

COVERAGE DETERMINATION REQUEST FORM

EOC ID:

Medically-Accepted Indication Prior Authorization

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

| Patient Name: | Prescriber Name: | |
|--|--|-----------------------------|
| Member/Subscriber Number: | Fax: | Phone: |
| Date of Birth: | Office Contact: | |
| Group Number: | NPI: | State Lic ID: |
| Address: | Address: | |
| City, State ZIP: | City, State ZIP: | |
| Primary Phone: | Specialty/facility name (if applicable | e): |
| *Please note that Elixir will process the request as writte | en, including drug name, with i | no substitution. |
| | ☐ Expedited/Urgent | |
| Drug Name and Strength: | | |
| | | |
| Directions / SIG: | | |
| Please attach any pertinent medical history or information | for this patient that may support | approval. Please answer the |
| | estions and sign. | |
| | | |
| Od to this assured for initial and a setting in a thousand | | |
| Q1. Is this request for initial or continuing therapy? | _ | |
| ☐ Initial therapy | ☐ Continuing therapy | |
| Q2. If the request is for CONTINUING THERAPY, pleas | e provide the start date (MM/YY) |): |
| ,,, | , | |
| OO Disass in the state the section the state of the state | . d | |
| Q3. Please indicate the patient's diagnosis for the requeste | ed medication: | |
| | | |
| Q4. Please list all other medications the patient has previo | usly tried for the indicated diagno | osis along with the dates |
| and outcomes (e.g. ineffective, adverse reaction, etc): | | |
| | | |
| Q5. Please provide any supporting clinical statements sucl | n as chart notes, lab values, adve | erse outcomes, treatment |
| failures, or any other additional clinical information to supp | ort an authorization request (if ne | eded): |
| | | |
| Q6. IF the request is for a compounded product, please ch | eck all that apply: | |
| ☐ The prescriber attests that the requested | ☐ The requested compou | nded product contains bulk |
| compounded product contains at least ONE prescription | powders | · |
| ingredient | ☐ The requested compou | nded product contain ONLY |
| ☐ The prescriber attests that the requested | over-the-counter ingredients | |
| compounded product is not a copy of a commercially | ☐ The request is for a ren | ewal and the prescriber |



COVERAGE DETERMINATION REQUEST FORM

EOC ID:

Medically-Accepted Indication Prior Authorization

Phone: 800-361-4542 Fax back to: 866-414-3453

Elixir manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

| Patient Name: | Prescriber Name: | | |
|---|--|--|--|
| available FDA-approved product Dosage form being compounded is due to the patient being unable to use the commercially available product Patient is unable to use a commercial available product due to a hypersensitivity or allergy to any of the components (i.e. dyes, preservatives, fragrances, gluten) There is a commercially available product shortage or discontinuation by the manufacturer | attests that patient has had disease stabilization or improvement with the use of this compounded product None of the above | | |
| Q7. IF the request is for a compounded product, please specify if the unique dosage form is considered standard of care based on credible scientific literature defined as one of the following (Check all that apply): Peer reviewed literature indexed in Medline CMS recognized pharmacy compendia (e.g. NCCN, DrugDex, and AHFS DI) Published clinical practice guidelines developed by multidisciplinary experts and clinicians affected by the guidelines (e.g. American Medical Association, Infectious Disease Society of America) Other None of the above | | | |
| | | | |
| accepted indication. Medically accepted indications are de under the Food, Drug, and Cosmetic Act or supported by r Recognized compendia are: American Hospital Formulary Comprehensive Cancer Network (NCCN), and Clinical Phaliterature may also be used to determine medically accepted Acceptable peer-reviewed medical literature includes: American Annals of Oncology, Annals of Surgical Oncology, Biology Transplantation, British Journal of Cancer, British Journal of Cancer Research, Drugs, European Journal of Cancer, Gy Oncology, Biology and Physics, The Journal of the American Journal of the National Cancer Institute, Journal of the Natlancet, Lancet Oncology, Leukemia, The New England Journal of | based on the criteria outlined in this paragraph and the libed are covered by the plan and being used for a medically fined by the plan as: Any use of a drug which is approved ecognized compendia or resources. Service Drug Information (AHFS), Micromedex, National armacology. When necessary, peer reviewed medical ed indications for anti-cancer chemotherapy requests. Erican Journal of Medicine, Annals of Internal Medicine, of Blood and Marrow Transplantation, Blood, Bone Marrow of Hematology, British Medical Journal, Cancer, Clinical recologic Oncology, International Journal of Radiation, an Medical Association, Journal of Clinical Oncology, ional Comprehensive Cancer Network, Journal of Urology, | | |



COVERAGE DETERMINATION REQUEST FORM

EOC ID:

Medically-Accepted Indication Prior Authorization

Phone: 800-361-4542 Fax back to: 866-414-3453

| | | uire review with the prescribing physician. Please an ation left blank or illegible may delay the review | swer |
|---------------------|---------------|--|------|
| Patient Name: | Prescriber Na | Prescriber Name: | |
| | | | |
| | | | |
| | | | |
| | | | |
| Prescriber Signatur | re | Date | |

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document